PDS Biotechnology (PDSB) Assets (2014 - 2026)
PDS Biotechnology's (PDSB) quarterly Assets came in at $30.5 million in Q4 2025, down 32.77% YoY from $45.4 million in Q4 2024, and down 12.14% on a QoQ basis from $34.7 million in Q3 2025.
PDS Biotechnology (PDSB) Assets (2014 - 2026) Analysis & Trends
PDS Biotechnology (PDSB) has 12 years of Assets data on file, last reported at $30.5 million in Q4 2025.
- Quarterly Assets fell 32.77% year-over-year to $30.5 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $30.5 million (down 32.77% YoY) and the FY2025 annual result came in at $30.5 million, down 32.77% from the prior year.
- Assets eased to $30.5 million in Q4 2025, from $34.7 million in the prior quarter.
- In the past five years, Assets ranged from a high of $77.4 million in Q2 2021 to a low of $27.8 million in Q1 2021.
- A 5-year average of $57.1 million and a median of $59.9 million in 2023 frame the typical range for Assets.
- Annual changes were most pronounced in 2021 — Assets soared 285.16% — and 2025, when it tumbled 33.83%.
- Tracing PDSB's Assets over 5 years: stood at $67.2 million in 2021, then advanced by 14.6% to $77.0 million in 2022, then fell by 22.88% to $59.4 million in 2023, then slipped by 23.63% to $45.4 million in 2024, then plunged by 32.77% to $30.5 million in 2025.
- The last three Assets figures came in at $30.5 million (Q4 2025), $34.7 million (Q3 2025), and $40.5 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.90 Bn | 131.05 Bn | 2.84 Bn | 27.42 Bn |
| 2 | Regeneron Pharmaceuticals | 86.10 Bn | 78.11 Bn | 3.93 Bn | 41.73 Bn |
| 3 | Argenx Se | 65.56 Bn | 60.37 Bn | 1.37 Bn | 10.03 Bn |
| 4 | Moderna | 55.82 Bn | 50.68 Bn | 52.00 Mn | 10.96 Bn |
| 5 | BeOne Medicines | 42.14 Bn | 37.04 Bn | 1.53 Bn | 9.18 Bn |
| 6 | Alnylam Pharmaceuticals | 31.67 Bn | 28.36 Bn | 992.69 Mn | 5.56 Bn |
| 7 | BioNTech SE | 27.74 Bn | 9.35 Bn | 668.28 Mn | 25.60 Bn |
| 8 | Insmed | 27.53 Bn | 26.37 Bn | 358.27 Mn | 2.10 Bn |
| 9 | Royalty Pharma | 27.38 Bn | 26.54 Bn | - | 19.82 Bn |
| 10 | PDS Biotechnology | 12.06 Mn | 12.06 Mn | - | 8.81 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 8.81 Mn |
| Dec 31, 2025 | 30.49 Mn |
| Sep 30, 2025 | 34.71 Mn |
| Jun 30, 2025 | 40.48 Mn |
| Mar 31, 2025 | 47.03 Mn |
| Dec 31, 2024 | 45.36 Mn |
| Sep 30, 2024 | 52.45 Mn |
| Jun 30, 2024 | 60.50 Mn |
| Mar 31, 2024 | 69.01 Mn |
| Dec 31, 2023 | 59.39 Mn |
| Sep 30, 2023 | 57.19 Mn |
| Jun 30, 2023 | 63.75 Mn |
| Mar 31, 2023 | 68.45 Mn |
| Dec 31, 2022 | 77.01 Mn |
| Sep 30, 2022 | 74.89 Mn |
| Jun 30, 2022 | 56.00 Mn |
| Mar 31, 2022 | 61.04 Mn |
| Dec 31, 2021 | 67.20 Mn |
| Sep 30, 2021 | 71.75 Mn |
| Jun 30, 2021 | 77.39 Mn |